Our offerings / Nordic RWE & Evidence Insights
Offering 02

Nordic real-world data, translated into decisions.

Nordic health data is high-quality, population-based and uniquely linkable. We help clients turn that into decision-ready evidence across clinical, commercial and market access needs.

Illustrative

Examples of the kinds of questions Nordic RWE can answer.

Why Nordic RWE

The right question, the right data, the right study design.

Nordic registries provide high-quality, population-based data that can be linked across national data sources. Few places in the world offer comparable longitudinal depth on whole populations.

Nordic RWE is most valuable when the right research question, the right data and the right study design come together. We know what Nordic data can answer, how to generate fit-for-purpose evidence, and how to translate findings into strategic decisions for clinical, commercial and market access teams.

450+Nordic RWE & Access projects
35+Published RWE studies, all therapy areas
80+Major global & EU5 projects
10+Standing cohorts, ready for feasibility

Wondering whether Nordic RWE can support your evidence need?

Two questions we hear most often, and the way Nordic real-world data answers each.

Clinical hypothesis

"We have a clinical hypothesis, but not the evidence to test it."

We can test clinical assumptions against real-world evidence on patients, treatments and outcomes, at population scale, with the rigour an HTA body or journal will accept.

Strategic use of data

"We know the data exists, but not how to use it strategically."

When the data exists but the way to use it is not obvious, we help shape it into analysis that supports planning, positioning and decisions.

&

We do both: rigorous, peer-reviewed studies and strategic, commercially-aimed analyses, and most often merge the two, so the same evidence base serves a regulatory dossier, a payer conversation and a commercial discussion.

Our edge

Two things that make our Nordic RWE different.

The infrastructure to do cross-Nordic linked RWE at scale, and the in-house access and engineering teams to turn that evidence into decisions teams can actually use.

Infrastructure

Computerome: our cross-Nordic compute backbone.

We hold access to Computerome, the Danish national life-science high-performance computing environment. Here, we can link, harmonise and analyse Nordic registry data securely, across markets, in one place, on infrastructure built for sensitive health data.

  • Secure, GDPR-compliant compute on Danish national life-science infrastructure
  • Cross-Nordic linkage and harmonisation pipelines we've built over years
  • Reusable analytical assets: standing cohorts, validated phenotypes, common variable definitions
ComputeromeLinked & harmonised
DK
SE
NO
FI
Inside one house

RWE built for access and communication.

Our Nordic RWE team works alongside NHTA's market access strategists and software engineers, under one roof. Evidence doesn't get handed off to a vendor: the same team that designs the study also builds the payer model, the field dashboard or the publication strategy.

RWE Generate the evidence
Access Embed in submission & pricing
Dashboards Make it usable for the team

How we work

From a research question to useful insights.

A four-step process every project follows, from articulating the decision the evidence has to support, all the way to a finding presented in the format the decision needs.

01

Define the evidence need

The decision the evidence has to support, before any data is touched.

02

Assess feasibility

The right data, the right population, the right study design.

03

Generate evidence

Fit-for-purpose RWE methods, not a one-size-fits-all template.

04

Translate insights

Findings shaped for the audience that will use them.

Across the product lifecycle

Three jobs for evidence, each with its own audience.

The question Nordic RWE has to answer changes as a brand moves from early planning to launch to clinical practice. We support the same three jobs across that lifecycle.

Pre-launch
Phase 01

Identify the opportunity

Understand the disease landscape, unmet need and patient population potential, before strategic decisions are locked in.

  • Epidemiology & incidence by Nordic market
  • Treatment pathways and standard-of-care benchmarks
  • Sub-population sizing for indication strategy
Launch
Phase 02

Build the evidence case

Strengthen evidence planning for early decision-making, launch readiness, market access submissions and positioning.

  • External control arms and comparator data
  • HTA-grade evidence for NICE / TLV / DMP / Fimea
  • Pricing and reimbursement support packages
Post-launch
Phase 03

Demonstrate real-world value

Show real-world treatment patterns, outcomes and value in clinical practice, to defend access and inform expansion.

  • Adherence, persistence and switching evidence
  • Outcomes-based contracting and managed access
  • Comparative effectiveness vs. real-world standard of care

Standing cohorts

Need data-driven answers quickly?

Using our pre-built Danish cohorts, we help clients quickly explore whether their evidence question can be answered with Nordic real-world data.

We start in Denmark, where deep, linkable registries make it a high-value starting point, then extend to the other Nordic countries as data is obtained.

We can support early feasibility by identifying relevant patient populations, available variables, outcomes and treatment patterns, so you understand what's possible before moving into a full RWE study.

Standing cohorts Pre-built · feasibility-ready

Let's talk

Got a question Nordic data might be able to answer?